REFERENCES
- Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italian() Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000;23:236–245.
- Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treat-ment: Swiss HIV Cohort Study. Lancet. 2001385: 1322–1327.
- Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170:229–238.
- Duval X, Journot V, Leport C, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-contain-ing therapy. Clin Infect Dis. 2004;39:248–255.
- Mathews WC, McCutchan JA, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV cost and services utilization study. Med Care. 2000; 38:750–762.
- Mocroft A, Phillips AN, Soriano V, et al. Reasons for stop-ping antiretrovirals used in an initial highly active antiretro-viral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepa-tititis C coinfection. AIDS Res Hum Retroviruses. 2005; 21:527–536.
- Kilbourne AM, Andersen RM, Asch S, et al. Response to symptoms among a U.S. national probability sample of adults infected with human immunodeficiency virus. Med Care Res Rev. 2002;59:36–58.
- Smeeth L, Douglas I, Hubbard R. Commentary: We still need observational studies of drugs - they just need to be better. Int J EpidemioL 2006;35: 1310–1311.
- Stephens RJ, Hopwood P, Girling DJ, Machin D. Random-ized trials with quality of life endpoints: Are doctors' rat-ings of patients' physical symptoms interchangeable with patients' self-ratings? Qua/ Life Res. 1997;6:225–236.
- Luck J, Peabody JW, Dresselhaus TR, Lee M, Glassman P. How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med. 2000;108:642–649.
- Brown EG. Effects of coding dictionary on signal gen-eration: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. 2002;25(6):445–452.
- Division of AIDS. Table for grading severity of adult adverse experiences, August 1992. Available at: http://rcc.tech-res-intl.com/tox_tables.htm
- Agresti A. Categorical Data Analysis. New York: John Wiley & Sons; 1990.
- Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability and clinical validity of pro-vider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic St/11dr 1999;21: 126–133.
- Justice AC, Chang CH, Rabeneck L, Zackin R. Clinical importance of provider-reported HIV symptoms compared with patient report. Med Care. 2001;39:397–408.
- Fontaine A, Larue F, Lassauniere JM. Physicians' recogni-tion of the symptoms experienced by patients: how reli-able? J Pain Symp Manage. 1999;18: 263–270.
- Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH. Differences in perceived and presented adverse drug reac-tions in general practice. J Clin EpidemioL 1998;51:795–799.
- Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin EpidemioL 2001;54:S77–S90.